论文部分内容阅读
本文应用差别聚合酶链式反应检测了６３例乳癌患者新鲜手术标本的Ｃ－ｅｒｂＢ－２基因。结果表明，共在１３例（２０６％）乳癌患者中检测出Ｃ－ｅｒｂＢ－２基因扩增。在有淋巴结转移的乳癌患者中，Ｃ－ｅｒｂＢ－２扩增的阳性率为２１６％（８／３７）；尚无淋巴结转移的患者中，阳性率为１９２％（５／２６）；两者无统计学差异（Ｐ＞０７５）。在５０例临床分期明确的病例中，Ⅲ期的Ｃ－ｅｒｂＢ－２扩增阳性检出率为５／１７；Ⅳ期为１／４；高于Ⅱ期４／２７及Ⅰ期０／２，但无统计学差异（Ｐ＞０５０）。
In this paper, C-erbB-2 gene was detected by differential polymerase chain reaction in 63 fresh breast cancer patients. The results showed that C-erbB-2 gene amplification was detected in 13 (20.6%) breast cancer patients. In breast cancer patients with lymph node metastases, the positive rate of C-erbB-2 amplification was 21.6% (8/37); in patients without lymph node metastasis, the positive rate was 19.2% (5/26). There was no statistical difference between the two (P>075). In 50 cases with clear clinical stages, the positive rate of C-erbB-2 amplification in stage III was 5/17; in stage IV, it was 1/4; it was higher than stage 4/27 and stage I 0/2. However, there was no statistical difference (P>050).